| Document |
Document Title |
|
WO/2024/084435A2 |
The present invention relates to a viscous liquid ophthalmic composition comprising or, alternatively, consisting of natural gums and extracts, in particular at least one mucilage and at least one hydrocolloid, useful, for example, as a ...
|
|
WO/2024/086194A1 |
The present disclosure describes methods of treating a subject suffering from cancer using a combination therapy comprising (i) administering to the subject a therapeutically-effective amount of a compound that blocks SUMOylation in the ...
|
|
WO/2024/085245A1 |
The purpose of the present invention is to provide a preparation that can effectively suppress post-operative delirium. A post-operative delirium suppressant according to the present invention is characterized by containing a GABA-A rece...
|
|
WO/2024/083221A1 |
A mucosal administration formulation, and a preparation method and use therefor. The preparation method for the mucosal administration formulation comprises the following steps: (1) mixing a nucleating agent solution, a drug protein solu...
|
|
WO/2024/084212A1 |
The present invention relates to a compound for use in a method of treating idiopathic pulmonary fibrosis in a patient, which compound is ensifentrine or a pharmaceutically acceptable salt thereof, wherein the method comprises administer...
|
|
WO/2024/085166A1 |
The present invention addresses the problem of: providing an anti-CLDN4-anti-CD137 bispecific antibody to be used in combination with a PD-1 signal inhibitor for treatment of a cancer, or a pharmaceutical composition comprising said bisp...
|
|
WO/2024/086316A1 |
A method of treating a cancer having one or more mutations in tumour suppressors AXIN1 and/or APC in the WNT pathway in a subject in need thereof is provided wherein the method comprises administering a MEK inhibitor or a pharmaceuticall...
|
|
WO/2024/086634A1 |
The application relates to heterocyclic heteroaromatic macrocyclic ether compounds of the general Formula (I), pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. The compounds act as selective inh...
|
|
WO/2024/083176A1 |
Disclosed are the uses of amniotic fluid in the preparation of a drug for treating and/or preventing macrophage-mediated diseases, a drug for treating and/or preventing type M1 macrophage-mediated diseases, a drug for treating and/or pre...
|
|
WO/2024/006804A3 |
Provided herein are methods of preventing or treating a tumor in a subject in need thereof, comprising administering to the subject a dose of a stimulator of interferon genes protein (STING) agonist, wherein the amount of the STING agoni...
|
|
WO/2024/086577A1 |
The present disclosure features methods useful for the treatment of BAF complex-related cancers.
|
|
WO/2024/083959A1 |
The present invention relates to the use of an anti-interleukin-6 agent prior to, simultaneously with, or after a CRS inducing immunotherapeutic agent.
|
|
WO/2024/083862A1 |
The present invention relates to floxuridine or a pharmaceutically acceptable salt, hydrate, solvate thereof for use in preventing and/or treating a bacterial infection, wherein said bacterial infection is caused by a gram negative bacte...
|
|
WO/2024/085247A1 |
One embodiment of the present invention provides a method for fusing lipid nanoparticles. In some embodiments, this method comprises: causing a fibrous structure to capture first lipid nanoparticles; causing the fibrous structure to capt...
|
|
WO/2024/039897A3 |
Pharmaceutical compositions in solid form comprising adagrasib, suitable for oral dosage to treat subjects having cancer; as well as methods of manufacturing the compositions, and methods of treating cancer. In one embodiment, the presen...
|
|
WO/2024/083716A1 |
The present specification relates a method of treating a patient with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), breast cancer comprising administering an oral selective estrogen receptor ...
|
|
WO/2024/081363A1 |
The disclosure features methods for treating cancer (e.g., immune refractory cancer) using a RAS inhibitor. The disclosure also features combination therapies containing one or more RAS inhibitors for treating cancer.
|
|
WO/2024/079009A1 |
The present invention relates to the combination therapy of anti-GPRC5D/anti-CD3 bispecific antibodies with proteasome inhibitors. The combination therapy may further comprise a glucocorticosteroid.
|
|
WO/2024/081372A1 |
The present invention relates to processes for the preparation of the compound of formula 1 from the intermediates the intermediates of formulae 8 to 10 in the presence of the cyclisation catalyst CuSO4 Compound 1 is the agent-linker con...
|
|
WO/2024/081404A1 |
The present disclosure is related to dietary supplements including compositions that include, one or more agents that increase γ-aminobutyric acid (GABA) binding with GABA-A receptor, increase serotonin concentrations, decrease dopamine...
|
|
WO/2024/080726A1 |
The present invention relates to a pharmaceutical composition containing natural killer cells and a topoisomerase inhibitor as active ingredients. The pharmaceutical composition according to the present invention exhibits cytotoxicity in...
|
|
WO/2023/183875A9 |
The disclosure features methods and compositions for the treatment of perivascular fibrosis and other hypertensive diseases and conditions, cardiovascular diseases, and chronic kidney disease.
|
|
WO/2024/077506A1 |
Atovaquone is used for treating and preventing acute and chronic inflammatory diseases in mammals, including mast cell-mediated inflammatory diseases.
|
|
WO/2024/081310A1 |
Described herein are engineered mammalian cells comprising a reduction in the level or function of one or more of a major histocompatibility complex (MHC) class I protein complex component, optionally, a MHC class II protein complex comp...
|
|
WO/2024/078568A1 |
Provided in the present invention are a treatment method for treating cancer patients accompanied by pain by using a combination of an AKR1C3 activated anticancer prodrug compound and an analgesic drug, a pharmaceutical use, a drug combi...
|
|
WO/2024/079364A1 |
The present invention relates to cladribine or a pharmaceutically acceptable salt, hydrate, solvate thereof for use in preventing and/or treating a bacterial infection, wherein said bacterial infection is caused by a gram negative bacter...
|
|
WO/2024/079603A1 |
The present invention relates to novel pharmaceutical formulations given by the association of an inhibitor of histone methyltransferase activity and chemotherapeutic drugs for use in the treatment of cancer, in particular of colon cance...
|
|
WO/2024/081932A1 |
Provided are methods for the treatment of spinal muscular atrophy (SMA) in a fetal subject in need thereof comprising administering an amount of risdiplam to a carrier of the fetal subject. Administering the amount of risdiplam to the ca...
|
|
WO/2024/081674A1 |
Provided are methods of treating cancer (e.g, a cancer that comprises one or more cancer cells that express a KRAS G12C mutant protein and/or have at least one mTOR- activating aberration) in an individual that comprise administering a c...
|
|
WO/2024/081916A1 |
The present disclosure relates to methods of treating or preventing cancer using a compound of Formula (0): or a pharmaceutically acceptable salt thereof. The present disclosure also relates to pharmaceutical compositions and pharmaceuti...
|
|
WO/2024/077856A1 |
Provided in the present invention is the use of a TBX family transcription factor as a target in the preparation of a drug for treating ophthalmic diseases. In the present invention, the TBX family transcription factor is used as a targe...
|
|
WO/2024/081309A1 |
Described herein are engineered mammalian cells comprising a reduction in the level or function of a major histocompatibility complex (MHC) class I protein complex component, and, optionally, a MHC class II protein complex component and/...
|
|
WO/2024/081969A1 |
Described herein are compounds, formulations, and methods for blocking sporozoite invasion and subsequent liver-stage parasite development of a protozoan parasite, such as Plasmodium falciparum. Also described herein are compounds, formu...
|
|
WO/2024/077099A1 |
Provided herein are methods of treating a cancer (e.g., a solid tumor) in a subject in need thereof. The present disclosure also provides methods of activating the immune system of a subject in need thereof (e.g., a subject having a canc...
|
|
WO/2024/074850A1 |
The present invention is directed to the treatment of mental disorders. For example, there is provided a combination of a rapid-acting indolealkylamine and a mood preparation agent for use in a method for treating a mental disorder the m...
|
|
WO/2024/074554A1 |
The present invention relates to compositions and methods for treating or preventing infections, in particular infections by intracellular parasites such as Cryptosporidium spp. The present invention also relates to compositions and meth...
|
|
WO/2024/077121A1 |
Oral care compositions that contain a particular mixture of mono-rhamnolipids and dirhamnolipids are disclosed. The compositions have antimicrobial efficacy against oral microbes, such as P. gingivalis, S. mutans, and C. rectus. Also dis...
|
|
WO/2024/074049A1 |
Provided are a pharmaceutical composition for thyroid undifferentiated cancer and use thereof in the preparation of a medicament for preventing and/or treating thyroid undifferentiated cancer. The pharmaceutical composition comprises jac...
|
|
WO/2024/074498A1 |
The present invention relates a therapeutic combination of a BTN3A activating antibody, a Bcl-2 family inhibitor and hypomethylating agents that is particularly useful for the treatment of cancer, in particular hematological malignancies...
|
|
WO/2024/075844A1 |
The present disclosure provides a technique for examining the acquisition risk of an inflammatory skin disease, the severity or the degree of progression thereof. The present disclosure provides a method for analyzing a biological sample...
|
|
WO/2024/076537A1 |
The present disclosure generally relates to technologies for treating cancer, including brain cancers such as a glioblastoma, methods of increasing the concentration of anthracy clines and immune checkpoint modulators in the brain of a s...
|
|
WO/2024/074959A1 |
This invention relates to talazoparib, or a pharmaceutically acceptable salt thereof, in combination with enzalutamide, or a pharmaceutically acceptable salt thereof, for the treatment of metastatic castration-resistant prostate cancer a...
|
|
WO/2024/075803A1 |
The present invention addresses the problem of providing: a method for testing a cranial nerve disease including schizophrenia, or a method for testing the sensitivity to a cranial nerve disease; and a reagent and a kit for use in the te...
|
|
WO/2024/075696A1 |
The present invention addresses the problem of providing a novel compound having an SMG1 inhibitory activity and an anticancer effect, or a pharmaceutically acceptable salt thereof etc. A compound represented by formula (1) or a pharma...
|
|
WO/2024/071464A1 |
The present invention relates to anticancer uses of a maleate metal salt. Particularly, the present invention relates to a pharmaceutical composition for preventing or treating cancer and an anticancer adjuvant pharmaceutical composition...
|
|
WO/2024/073451A1 |
Provided herein are compositions, such as suitable for subcutaneous administration, and methods for treating ascites in an individual using a mixed V1A receptor agonist-antagonist.
|
|
WO/2024/067891A2 |
Disclosed in the present application are the use of an Aldo-Keto reductase family 1 member C3 (AKR1C3) inhibitor in the inhibition of lipid droplet generation and the promotion of lipid droplet degradation and in the preparation of a dru...
|
|
WO/2024/073356A1 |
The disclosure relates to 2-[2-ethoxy-4-(ethylsulfanyl)-5-methoxyphenyl]ethan-1-aminiu
m chloride (2-(2-ethoxy-4-(ethylthio)-5-methoxyphenyl)ethan-1-a minium chloride), crystalline 2-(2-ethoxy-4-(ethylthio)-5-methoxyphenyl)ethan-1-aminiu...
|
|
WO/2024/073473A1 |
Provided herein are methods of treating non-hemorrhagic closed head injury (NHCHI) with 3,3'-diindolylmethane or an analog thereof. In one embodiment, NHCHI covers Traumatic Brain Injuries (TBIs) including mild to severe concussion, blas...
|
|
WO/2024/073672A1 |
The present disclosure relates to methods of treating a kidney disease or disorder, including methods comprising administering sparsentan and a SGLT2 inhibitor to a subject in need thereof.
|
